Alert detail

LCD L39940: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — CGS

Policy ID: LCD-L39940Specialty: Clinical LaboratoryAdded: 6/5/2026Effective: March 19, 2026lcd
High

What changed

New LCD on hereditary amyloidosis testing affects billing practices.

Who’s affected: Clinical Laboratory billing teams · Effective: March 19, 2026

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 4 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Clinical Laboratory— the week’s changes and deadlines, delivered to your inbox. No account required.